PARP1 and ovarian carcinoma: Taken the significant improvement in patients’ benefit observed in earlier therapeutic settings, along with the likelihood of long-term tolerability of PARP inhibitors, there is great potential for this drug class to become a foundation treatment for ovarian cancer, and far beyond BRCA1/2 mutant tumors.